12th Jun 2024 20:56
(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.
The pharmaceutical firm said the drug has been backed by the US Food & Drug Administration to treat patients aged 10 years and older with type-2 diabetes.
"Farxiga was previously approved in the US in adults with T2D as an adjunct to diet and exercise to improve glycaemic control," AstraZeneca said.
"Additional regulatory submissions and rollout plans are under consideration pending further market evaluations."
Shares in the company closed 0.6% higher at 12,446.00 pence each in London on Wednesday.
By Eric Cunha, Alliance News news editor
Comments and questions to [email protected]
Copyright 2024 Alliance News Ltd. All Rights Reserved.
Related Shares:
Astrazeneca